Select Page

Beovu’s Failure to Warn About Risks Results in Litigation


Beovu is a medication that was manufactured by the company Novartis for the treatment of wet age-related macular degeneration or AMD. In 2019, the FDA approved the drug. In February 2020, the American Society of Retina Specialists issued a warning pertaining to potential side effects, where they cited 14 cases of retinal inflammation in patients that had undergone Beovu injections. These numbers later increased to cases of retinal vasculitis and retinal occlusion.

First Filed Claim

The first Beovu claim was filed in the US District Court for the District of Nebraska, alleging that Novartis and Alcon Research, LLC. failed to adequately warn users in the medical community about vision risks associated with the medication.

Legal Question

Currently, the legal issue facing the case is whether Novartis failed to adequately warn doctors and patients about the potential vision-related side effects directly caused by the Beovu injections.

Allegation Against Novartis

The primary allocation is that Novartis negligently misrepresented the safety of the injections in their label, and thus, if patients were to have known of the risks associated with Beovu, it is unlikely they would have been prescribed or used the drug. [1]

Research Studies and Side Effects  

Researchers with the American Society of Retina Specialists first raised concerns about vision risks associated with the medication last year. Also, according to the National Library of Medicine, there are several side effects from the drug that can lead to very serious complications[2] that require emergency medical treatment. These side effects are listed below:

  • Changes in vision
  • Pain or redness in the eye
  • Sensitivity to light
  • Bleeding in or around the eye
  • Vision affected by “floaters” and/or small specks
  • Hives, rash, redness, or itching
  • Swelling of the eyelid or the eye

Label Change

Because of the recent issues and side effects, some physicians have chosen to stop carrying or prescribing the injection drug in their inventories. Additionally, the FDA required that Novartis add a new warning label regarding the retinal vasculitis in June 2020. However, the risks are still not yet fully known.


Additionally, some of the injuries from the Beovu injection claims currently in litigation are:

  • Retinal vasculitis
  • Retinal artery occlusion
  • Occlusive retinal vasculitis
  • Vision loss
  • Blindness

If you or a loved one have been injured by Beovu, please contact us at the Michael Brady Lynch Firm at 888-585-5970. The consultation is completely free and confidential.



Adverse Events Linked to the Drug Xeljanz

Adverse Events Linked to the Drug Xeljanz

Xeljanz has been marketed and sold to consumers in the United States for nearly a decade, manufactured by the Pfizer pharmaceutical company. Xeljanz and Xeljanz XR are the brand names for the drug...

read more
FDA Recalls Surgical Abdominal Mesh

FDA Recalls Surgical Abdominal Mesh

Abdominal Mesh blog Hernias occur when part of the tissue in the abdominal area, such as the intestines, pushes through a hole or weak area in the connective tissue in the abdomen. Currently, there...

read more
What is Multidistrict Litigation?

What is Multidistrict Litigation?

Multidistrict litigation is a process that the United States District Court uses to “centralize complex lawsuits for pre-trial proceedings.”[i] The process is used because there are multiple...

read more
What Our Clients Are Saying